Not independent
Tenure on this board
8.1 yrs
Meeting calendar
TTRX · Annual meeting · Monday, November 30, 2026
Turn Therapeutics Inc
2 nominees · 2 ballot items.
Stockholders will vote on the election of two Class I directors and ratification of WithumSmith+Brown, PC as the Company’s independent registered public accounting firm for fiscal year 2026.
Market cap
$320M
1Y TSR
+124.0%
Board grade
B
Record date
Oct 5, 2026
Filing
DEF 14A
Filed Oct 19, 2026 · DEF 14A
Proposals
On the ballot2
- 1
Election of Class I Directors
ManagementBoard: FORElect Bradley Burnam and Dr. Neil Ghodadra as Class I directors to serve until the 2029 annual meeting of stockholders.
- 2
Ratification of Selection of Independent Registered Public Accounting Firm
ManagementBoard: FORRatify the Audit Committee’s appointment of WithumSmith+Brown, PC as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
Director elections
Nominees on the ballot2
Dr. Neil Ghodadra
Not independent
Tenure on this board
New nominee
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | SteelPeak Wealth, LLC | 0.8% | 249,456 | $2M |
| 2 | IEQ CAPITAL, LLC | 0.8% | 227,396 | $2M |
| 3 | DDFG, Inc | 0.4% | 107,829 | $787K |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 0.2% | 74,301 | $542K |
| 5 | Wellington Shields & Co., LLC | 0.2% | 65,732 | $480K |
| 6 | MILLENNIUM MANAGEMENT LLC | 0.2% | 60,551 | $442K |
| 7 | BlackRock, Inc. | 0.1% | 36,232 | $264K |
| 8 | Aaron Wealth Advisors LLC | 0.1% | 32,564 | $238K |
| 9 | Tamar Securities, LLC | 0.1% | 30,000 | $219K |
| 10 | ROYAL BANK OF CANADA | 0.1% | 28,250 | $206K |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Turn Therapeutics Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Galectin Therapeutics IncGALT
Annual meeting·Dec 3, 2026·$353M
Tilray Brands IncTLRY
Annual meeting·Nov 18, 2026·$448M
Angiodynamics IncANGO
Annual meeting·Nov 17, 2026·$479M
Entera Bio LtdENTX
Special meeting·Nov 24, 2026·$506M
Weave Communications IncWEAV
Special meeting·Oct 22, 2026·$592M
Wave Life Sciences IncWVE
Annual meeting·Nov 12, 2026·$625M
Reference
Frequently asked questions
- When is the Turn Therapeutics Inc 2026 annual meeting?
- Turn Therapeutics Inc (TTRX) holds its 2026 annual shareholder meeting on Monday, November 30, 2026.
- What is the record date for the Turn Therapeutics Inc 2026 meeting?
- The record date for the Turn Therapeutics Inc 2026 meeting is Monday, October 5, 2026. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Turn Therapeutics Inc's 2026 meeting?
- The board is presenting 2 director nominees at the Turn Therapeutics Inc 2026 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Turn Therapeutics Inc 2026 meeting?
- Shareholders will vote on 2 proposals at the Turn Therapeutics Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.